TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07481383: A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

Sponsor: Continuity Biosciences, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,078,768

Rescue Site Savings

+$2,042,040

Unlock Full NCT07481383 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07481383 Rescue Dossier →